Cytodyn Inc (CYDY)

[HFM2]

My theory:

1. Leronlimab works amazingly with a very strong safety profile.

2. This makes it attractive to the medical profession.

3. It has multiple indications.

4. This makes it attractive to the medical profession.

5. Demand for certain other drugs will be reduced significantly if Leronlimab is approved for the indications it has trialed for.

6. This makes it attractive to the medical profession.

7. Large (other) Pharma do not like to see money flow from their coffers to others (standard business practice).

8. CYDY will soon be uplisted to Nasdaq, which bring certain benefits with it that will positively affect the company's ability to continue to test Leronlimab.

9. The drugs of other Pharma companies are under greater threat for reduced revenue the closer CYDY gets to approvals and uplisting.

10. One way to negatively affect CYDY is to have your favorite hired gun short the hell out of it at every turn, or at least at strategic places in the development process.

11. I think this is likely what is happening now, whether or not it is what happened back in June's run up.

12. Summary: the effectiveness of Leronlimab across multiple indications and the imminent Nasdaq uplisting are strong motives for certain companies whose revenues may be affected by Leronlimab approvals to engage in shorting. Do I have video evidence of any particular group shorting this stock today? No. Is it likely? Yes.